Search research articles
Contact Us
Filters
Showing results (91-100 of 138) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Cancer
|
August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials
Sebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
The Oncologist
|
May 30, 2013
Ipilimumab for patients with advanced mucosal melanoma
Michael A Postow, Jason J Luke, Mark J Bluth, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
The Lancet. Oncology
|
June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J Harding, Jia Fan, Do-Youn Oh, et al.
JAMA Oncology
|
November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
Shubham Pant, Jia Fan, Do-Youn Oh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectory
Elyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 138) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Cancer
|
August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials
Sebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
The Oncologist
|
May 30, 2013
Ipilimumab for patients with advanced mucosal melanoma
Michael A Postow, Jason J Luke, Mark J Bluth, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
The Lancet. Oncology
|
June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J Harding, Jia Fan, Do-Youn Oh, et al.
JAMA Oncology
|
November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
Shubham Pant, Jia Fan, Do-Youn Oh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectory
Elyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
Page
of 14